长春高新：GenSci134注射液境内生产药品注册临床试验申请获批准

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Clinical Trial Approval Notice from the National Medical Products Administration for the domestic production registration clinical trial application of GenSci134 injection [1] Group 1 - GenSci134 injection is a Class 1 therapeutic biological product independently developed by Jinsai Pharmaceutical [1] - The drug is intended for the treatment of Growth Hormone Deficiency (GHD), including Adult Growth Hormone Deficiency (AGHD), Pediatric Growth Hormone Deficiency (PGHD), and non-GHD patients (including ISS) [1] - The current application specifically targets Idiopathic Short Stature (ISS) [1]